ONCOseeker™ Solid
Cancer diagnostic NGS kit using hybridization capture method
ONCOseeker™ Solid is a hybridization capture-based solid cancer diagnostic panel that provides patient prognosis prediction and diagnostic information.
Based on next-generation sequencing (NGS) technology, our panel provides optimal treatment information for cancer patients in a short time with a single test and predicts the course of the disease after treatment, helping to customize treatment.
Introduction
Cell-free DNA or gDNA from FFPE
*FFPE : Formalin Fixed Paraffin Embedded tissue
ONCOseeker™ is a solid cancer diagnostic panel based on a hybridization capture method that provides prediction and diagnosis information for patients. Not only gDNA extracted from FFPE and cell-free DNA extracted from blood can be applied to the panel.
Hybridization capture using a probe
A panel system that detects mutant genes using the characteristics of biotin, which has a specific binding to probes. It can check the target’s mutation by using a probe that specifically binds to the target region. A DNA, bound to the probe can be captured using a magnetic bead.
Next Generation Sequencing (NGS) & Analysis
A library captured by using beads is available with enrichment through PCR. The amplified library is generated from ONCOseeker™ panel data through NGS sequencing equipment. The data can be analyzed through GeneCker’s in-house database analysis program, PinAnalysis™.
Lineup
ONCOseeker™ Solid is an NGS (Next-generation sequencing) based solid cancer diagnostic panel with a hybridization capture method of major genetic mutations related to solid tumors. It consists of 45 genes specialized for solid cancer patients following clinical diagnosis guidelines to detect various genetic mutations and provide an accurate high-quality analysis.
ONCOseeker™ Solid is a small-medium size and can be used not only in big hospitals but also in small hospitals. Based on clinical evidence, it provides optimal treatment and drug information in a short period. Also, it can predict the progress (prognosis) of the disease after treatment for customized treatment.
Product Specification
| ONCOseeker™ Solid | ||
|---|---|---|
| Input DNA | FFPE 200 ng cell free DNA 20 ng |
|
| Target enrichment | Hybridization-captured | |
| Platform | Illumina MiSeqDx MiSeq reagent v2 or v3 |
|
| Target Size | Size : 144 kb Gene : 45 |
|
| Applications | Indel, SNV, CNV | |
| Library prep time | ≤ 2~2.5 days | |
| Analysis solution | PinAnalysis™ | |
| Target Hotspot List | |||||
|---|---|---|---|---|---|
| AKT1 | BRIP1 | FANCL | KIT | NRAS | SMAD4 |
| ALK | CDK12 | FBXW7 | KRAS | PALB2 | SMARCA4 |
| APC | CDKN2A | FGFR2 | MDM2 | PDGFRA | SMARCB1 |
| AR | CHEK2 | FGFR3 | MET | PIK3CA | STK11 |
| ATM | CTNNB1 | GNAS | MTOR | PTEN | TP53 |
| BRAF | EGFR | HRAS | MYC | PTPN11 | |
| BRCA1 | ERBB2 | IDH1 | MYCN | RET | |
| BRCA2 | ESR1 | IDH2 | NF1 | ROS1 | |
Performance evaluation
| Total Specification | |||
|---|---|---|---|
| Sensitivity | 100% | ||
| Specificity | 100% | ||
| Accuracy | PPA | 90% | (Positive Percentage Agreement) |
| PPV | 100% | (Positive Predictive Value) | |
| LOD | SNV | 1.0% VAF |
(Limit Of Detection) |
| INDEL | 1.0% VAF | ||
| SNV | PPA | 96.4% | (Positive Percentage Agreement) |
| PPV | 100% | (Positive Predictive Value) | |
| INDEL | SNV | 84.2% | (Positive Percentage Agreement) |
| INDEL | 100% | (Positive Predictive Value) |
Library preparation process
